Wall Street analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) to post ($0.10) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Caladrius Biosciences’ earnings, with estimates ranging from ($0.12) to ($0.06). Caladrius Biosciences also reported earnings per share of ($0.10) in the same quarter last year. The company is scheduled to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Caladrius Biosciences will report full year earnings of ($0.40) per share for the current year, with EPS estimates ranging from ($0.51) to ($0.25). For the next financial year, analysts forecast that the company will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.42) to ($0.31). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Caladrius Biosciences.
Caladrius Biosciences (NASDAQ:CLBS – Get Rating) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. During the same period in the previous year, the business earned ($0.19) earnings per share.
Shares of CLBS opened at $0.45 on Friday. The stock’s fifty day simple moving average is $0.64 and its 200 day simple moving average is $0.79. Caladrius Biosciences has a twelve month low of $0.40 and a twelve month high of $1.68.
A number of hedge funds and other institutional investors have recently made changes to their positions in CLBS. Renaissance Technologies LLC increased its holdings in Caladrius Biosciences by 11.8% in the 3rd quarter. Renaissance Technologies LLC now owns 1,747,055 shares of the biotechnology company’s stock valued at $2,131,000 after purchasing an additional 184,223 shares in the last quarter. Virtu Financial LLC acquired a new stake in Caladrius Biosciences in the 4th quarter valued at $135,000. Alterna Wealth Management Inc. acquired a new stake in Caladrius Biosciences in the 4th quarter valued at $61,000. Morgan Stanley grew its stake in shares of Caladrius Biosciences by 533.0% during the first quarter. Morgan Stanley now owns 70,537 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 59,393 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Caladrius Biosciences during the second quarter valued at about $87,000. Hedge funds and other institutional investors own 18.76% of the company’s stock.
Caladrius Biosciences Company Profile (Get Rating)
Caladrius Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.
- Get a free copy of the StockNews.com research report on Caladrius Biosciences (CLBS)
- VMWare Inc: Strong Revenues and Excellent Potential
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.